Galmed Pharmaceuticals Q3 2023 Earnings Report

Galmed Pharmaceuticals EPS Results

• Actual EPS: -$2.88
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Galmed Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Galmed Pharmaceuticals Announcement Details

• Quarter: Q3 2023
• Date: 11/22/2023
• Time: N/A

Galmed Pharmaceuticals (NASDAQ:GLMD), a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.